Integrin β


Journal

Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886

Informations de publication

Date de publication:
12 2019
Historique:
received: 17 04 2019
revised: 08 07 2019
accepted: 15 07 2019
pubmed: 23 8 2019
medline: 20 3 2021
entrez: 22 8 2019
Statut: ppublish

Résumé

Hepatic recruitment of monocyte-derived macrophages (MoMFs) contributes to the inflammatory response in non-alcoholic steatohepatitis (NASH). However, how hepatocyte lipotoxicity promotes MoMF inflammation is unclear. Here we demonstrate that lipotoxic hepatocyte-derived extracellular vesicles (LPC-EVs) are enriched with active integrin β Hepatocytes were treated with either vehicle or the toxic lipid mediator lysophosphatidylcholine (LPC); EVs were isolated from the conditioned media and subjected to proteomic analysis. C57BL/6J mice were fed a diet rich in fat, fructose, and cholesterol (FFC) to induce NASH. Mice were treated with anti-ITGβ Ingenuity® Pathway Analysis of the LPC-EV proteome indicated that ITG signaling is an overrepresented canonical pathway. Immunogold electron microscopy and nanoscale flow cytometry confirmed that LPC-EVs were enriched with activated ITGβ Lipotoxic EVs mediate monocyte adhesion to LSECs mainly through an ITGβ Herein, we report that a cell adhesion molecule termed integrin β

Sections du résumé

BACKGROUND & AIMS
Hepatic recruitment of monocyte-derived macrophages (MoMFs) contributes to the inflammatory response in non-alcoholic steatohepatitis (NASH). However, how hepatocyte lipotoxicity promotes MoMF inflammation is unclear. Here we demonstrate that lipotoxic hepatocyte-derived extracellular vesicles (LPC-EVs) are enriched with active integrin β
METHODS
Hepatocytes were treated with either vehicle or the toxic lipid mediator lysophosphatidylcholine (LPC); EVs were isolated from the conditioned media and subjected to proteomic analysis. C57BL/6J mice were fed a diet rich in fat, fructose, and cholesterol (FFC) to induce NASH. Mice were treated with anti-ITGβ
RESULTS
Ingenuity® Pathway Analysis of the LPC-EV proteome indicated that ITG signaling is an overrepresented canonical pathway. Immunogold electron microscopy and nanoscale flow cytometry confirmed that LPC-EVs were enriched with activated ITGβ
CONCLUSIONS
Lipotoxic EVs mediate monocyte adhesion to LSECs mainly through an ITGβ
LAY SUMMARY
Herein, we report that a cell adhesion molecule termed integrin β

Identifiants

pubmed: 31433301
pii: S0168-8278(19)30460-X
doi: 10.1016/j.jhep.2019.07.019
pmc: PMC6864271
mid: NIHMS1536747
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Integrin beta1 0
Itgb1 protein, mouse 0
Lysophosphatidylcholines 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1193-1205

Subventions

Organisme : NIDDK NIH HHS
ID : K08 DK111397
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK084567
Pays : United States

Informations de copyright

Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Références

J Hepatol. 2019 Mar;70(3):531-544
pubmed: 30414863
Hepatology. 2010 Aug;52(2):774-88
pubmed: 20683968
Hepatology. 2016 Mar;63(3):731-44
pubmed: 26406121
Blood. 2006 Feb 1;107(3):965-72
pubmed: 16210341
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
J Cell Sci. 2006 Oct 1;119(Pt 19):3901-3
pubmed: 16988024
Nat Commun. 2014 May 21;5:3869
pubmed: 24844798
Nat Commun. 2015 May 13;6:7164
pubmed: 25968605
Dev Cell. 2019 Feb 25;48(4):554-572.e7
pubmed: 30745140
Nat Rev Immunol. 2017 May;17(5):306-321
pubmed: 28317925
Integr Biol (Camb). 2015 Jul;7(7):815-24
pubmed: 26108037
Gastroenterology. 2016 Apr;150(4):956-67
pubmed: 26764184
Cell Mol Immunol. 2016 May;13(3):347-53
pubmed: 27041636
PLoS One. 2014 Dec 03;9(12):e113651
pubmed: 25470250
Hepatology. 2018 May;67(5):1754-1767
pubmed: 28833331
PLoS One. 2012;7(12):e52411
pubmed: 23285030
Dev Cell. 2019 Feb 25;48(4):573-589.e4
pubmed: 30745143
Hepatology. 2005 Oct;42(4):880-5
pubmed: 16175608
Am J Physiol Gastrointest Liver Physiol. 2012 Jan 1;302(1):G77-84
pubmed: 21995961
Mol Cell. 2019 Apr 4;74(1):32-44.e8
pubmed: 30846318
Cell. 2002 Sep 20;110(6):673-87
pubmed: 12297042
Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):145-159
pubmed: 30482910
Hepatology. 2009 Nov;50(5):1412-20
pubmed: 19708080
Nat Rev Drug Discov. 2016 Mar;15(3):173-83
pubmed: 26822833
Dev Cell. 2014 Jul 14;30(1):61-70
pubmed: 24954024
Curr Opin Cell Biol. 2015 Oct;36:41-7
pubmed: 26189062
Hepatology. 2017 Mar;65(3):969-982
pubmed: 28035785
Am J Physiol Gastrointest Liver Physiol. 2017 Jun 1;312(6):G666-G680
pubmed: 28232454
J Cell Sci. 2012 Aug 15;125(Pt 16):3695-701
pubmed: 23027580
JCI Insight. 2017 Aug 3;2(15):
pubmed: 28768902
Hepatology. 2016 Dec;64(6):2219-2233
pubmed: 27628960
Liver Int. 2017 Jan;37 Suppl 1:81-84
pubmed: 28052624
Science. 2003 Oct 3;302(5642):103-6
pubmed: 14526080
Biochim Biophys Acta Proteins Proteom. 2019 Dec;1867(12):140203
pubmed: 30822540
J Cell Biochem. 2017 Oct;118(10):3249-3259
pubmed: 28262979

Auteurs

Qianqian Guo (Q)

Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, Minnesota, United States.

Kunimaro Furuta (K)

Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, Minnesota, United States.

Fabrice Lucien (F)

Department of Urology, Mayo Clinic, Rochester, Minnesota, United States.

Luz Helena Gutierrez Sanchez (LH)

Division of Pediatric Gastroenterology, Mayo Clinic, Rochester, Minnesota, United States.

Petra Hirsova (P)

Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, Minnesota, United States.

Anuradha Krishnan (A)

Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, Minnesota, United States.

Ayano Kabashima (A)

Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, Minnesota, United States.

Kevin D Pavelko (KD)

Department of Immunology, Mayo Clinic, Rochester, Minnesota, United States.

Benjamin Madden (B)

Proteomics Core Medical Genome Facility, Mayo Clinic, Rochester, Minnesota, United States.

Husam Alhuwaish (H)

School of Medicine, The Royal College of Surgeons in Ireland, Ireland.

Yandong Gao (Y)

Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, United States.

Alexander Revzin (A)

Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, United States.

Samar H Ibrahim (SH)

Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, Minnesota, United States; Division of Pediatric Gastroenterology, Mayo Clinic, Rochester, Minnesota, United States. Electronic address: ibrahim.samar@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH